AMA
Ongoing (and increasing drug) shortages across the U.S. healthcare system continue to negatively affect patient care, leading to new policies from the American Medical Association that focus on diversifying manufacturing and stabilizing the generic market. Challenges from declines in domestic manufacturing to supply chain delays with overseas generic manufacturers, as well as an evolving prescribing landscape, the effect of advertising on patient demand, and general economic fragility within the drug industry all contribute to the ongoing shortages.
With updated AMA policies and initiatives to encourage government action in place, the organization is taking steps in the right direction, and plans to remain vigilant in tackling widespread issues that contribute medication shortages across the country.